Global Hepatic Antiviral Drug Market Size, Status and Forecast 2020-2026
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hepatic Antiviral Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Hepatic Antiviral Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Entecavir
1.4.3 Tenofovir
1.4.4 lamivudine
1.4.5 Adefovir
1.4.6 Telbivudine
1.4.7 Others
1.5 Market by Application
1.5.1 Global Hepatic Antiviral Drug Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Homecare
1.5.4 Clinics
1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Hepatic Antiviral Drug Industry Impact
1.6.1 How the Covid-19 is Affecting the Hepatic Antiviral Drug Industry
1.6.1.1 Hepatic Antiviral Drug Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Hepatic Antiviral Drug Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Hepatic Antiviral Drug Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends by Regions
2.1 Hepatic Antiviral Drug Market Perspective (2015-2026)
2.2 Hepatic Antiviral Drug Growth Trends by Regions
2.2.1 Hepatic Antiviral Drug Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hepatic Antiviral Drug Historic Market Share by Regions (2015-2020)
2.2.3 Hepatic Antiviral Drug Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter's Five Forces Analysis
2.3.5 Hepatic Antiviral Drug Market Growth Strategy
2.3.6 Primary Interviews with Key Hepatic Antiviral Drug Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hepatic Antiviral Drug Players by Market Size
3.1.1 Global Top Hepatic Antiviral Drug Players by Revenue (2015-2020)
3.1.2 Global Hepatic Antiviral Drug Revenue Market Share by Players (2015-2020)
3.1.3 Global Hepatic Antiviral Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hepatic Antiviral Drug Market Concentration Ratio
3.2.1 Global Hepatic Antiviral Drug Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hepatic Antiviral Drug Revenue in 2019
3.3 Hepatic Antiviral Drug Key Players Head office and Area Served
3.4 Key Players Hepatic Antiviral Drug Product Solution and Service
3.5 Date of Enter into Hepatic Antiviral Drug Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Hepatic Antiviral Drug Historic Market Size by Type (2015-2020)
4.2 Global Hepatic Antiviral Drug Forecasted Market Size by Type (2021-2026)
5 Hepatic Antiviral Drug Breakdown Data by Application (2015-2026)
5.1 Global Hepatic Antiviral Drug Market Size by Application (2015-2020)
5.2 Global Hepatic Antiviral Drug Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hepatic Antiviral Drug Market Size (2015-2020)
6.2 Hepatic Antiviral Drug Key Players in North America (2019-2020)
6.3 North America Hepatic Antiviral Drug Market Size by Type (2015-2020)
6.4 North America Hepatic Antiviral Drug Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hepatic Antiviral Drug Market Size (2015-2020)
7.2 Hepatic Antiviral Drug Key Players in Europe (2019-2020)
7.3 Europe Hepatic Antiviral Drug Market Size by Type (2015-2020)
7.4 Europe Hepatic Antiviral Drug Market Size by Application (2015-2020)
8 China
8.1 China Hepatic Antiviral Drug Market Size (2015-2020)
8.2 Hepatic Antiviral Drug Key Players in China (2019-2020)
8.3 China Hepatic Antiviral Drug Market Size by Type (2015-2020)
8.4 China Hepatic Antiviral Drug Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hepatic Antiviral Drug Market Size (2015-2020)
9.2 Hepatic Antiviral Drug Key Players in Japan (2019-2020)
9.3 Japan Hepatic Antiviral Drug Market Size by Type (2015-2020)
9.4 Japan Hepatic Antiviral Drug Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hepatic Antiviral Drug Market Size (2015-2020)
10.2 Hepatic Antiviral Drug Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hepatic Antiviral Drug Market Size by Type (2015-2020)
10.4 Southeast Asia Hepatic Antiviral Drug Market Size by Application (2015-2020)
11 India
11.1 India Hepatic Antiviral Drug Market Size (2015-2020)
11.2 Hepatic Antiviral Drug Key Players in India (2019-2020)
11.3 India Hepatic Antiviral Drug Market Size by Type (2015-2020)
11.4 India Hepatic Antiviral Drug Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hepatic Antiviral Drug Market Size (2015-2020)
12.2 Hepatic Antiviral Drug Key Players in Central & South America (2019-2020)
12.3 Central & South America Hepatic Antiviral Drug Market Size by Type (2015-2020)
12.4 Central & South America Hepatic Antiviral Drug Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Teva Pharmaceutical Industries
13.1.1 Teva Pharmaceutical Industries Company Details
13.1.2 Teva Pharmaceutical Industries Business Overview and Its Total Revenue
13.1.3 Teva Pharmaceutical Industries Hepatic Antiviral Drug Introduction
13.1.4 Teva Pharmaceutical Industries Revenue in Hepatic Antiviral Drug Business (2015-2020))
13.1.5 Teva Pharmaceutical Industries Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.2.3 Bristol-Myers Squibb Hepatic Antiviral Drug Introduction
13.2.4 Bristol-Myers Squibb Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Zydus Cadila
13.3.1 Zydus Cadila Company Details
13.3.2 Zydus Cadila Business Overview and Its Total Revenue
13.3.3 Zydus Cadila Hepatic Antiviral Drug Introduction
13.3.4 Zydus Cadila Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.3.5 Zydus Cadila Recent Development
13.4 Cipla
13.4.1 Cipla Company Details
13.4.2 Cipla Business Overview and Its Total Revenue
13.4.3 Cipla Hepatic Antiviral Drug Introduction
13.4.4 Cipla Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.4.5 Cipla Recent Development
13.5 Prinston Pharmaceutical
13.5.1 Prinston Pharmaceutical Company Details
13.5.2 Prinston Pharmaceutical Business Overview and Its Total Revenue
13.5.3 Prinston Pharmaceutical Hepatic Antiviral Drug Introduction
13.5.4 Prinston Pharmaceutical Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.5.5 Prinston Pharmaceutical Recent Development
13.6 Hetero Drug
13.6.1 Hetero Drug Company Details
13.6.2 Hetero Drug Business Overview and Its Total Revenue
13.6.3 Hetero Drug Hepatic Antiviral Drug Introduction
13.6.4 Hetero Drug Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.6.5 Hetero Drug Recent Development
13.7 Aurobindo Pharma
13.7.1 Aurobindo Pharma Company Details
13.7.2 Aurobindo Pharma Business Overview and Its Total Revenue
13.7.3 Aurobindo Pharma Hepatic Antiviral Drug Introduction
13.7.4 Aurobindo Pharma Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.7.5 Aurobindo Pharma Recent Development
13.8 Apotex
13.8.1 Apotex Company Details
13.8.2 Apotex Business Overview and Its Total Revenue
13.8.3 Apotex Hepatic Antiviral Drug Introduction
13.8.4 Apotex Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.8.5 Apotex Recent Development
13.9 Gilead Sciences
13.9.1 Gilead Sciences Company Details
13.9.2 Gilead Sciences Business Overview and Its Total Revenue
13.9.3 Gilead Sciences Hepatic Antiviral Drug Introduction
13.9.4 Gilead Sciences Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.9.5 Gilead Sciences Recent Development
13.10 Mylan
13.10.1 Mylan Company Details
13.10.2 Mylan Business Overview and Its Total Revenue
13.10.3 Mylan Hepatic Antiviral Drug Introduction
13.10.4 Mylan Revenue in Hepatic Antiviral Drug Business (2015-2020)
13.10.5 Mylan Recent Development
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of TablesTable 1. Hepatic Antiviral Drug Key Market Segments
Table 2. Key Players Covered: Ranking by Hepatic Antiviral Drug Revenue
Table 3. Ranking of Global Top Hepatic Antiviral Drug Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hepatic Antiviral Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Entecavir
Table 6. Key Players of Tenofovir
Table 7. Key Players of lamivudine
Table 8. Key Players of Adefovir
Table 9. Key Players of Telbivudine
Table 10. Key Players of Others
Table 11. COVID-19 Impact Global Market: (Four Hepatic Antiviral Drug Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Hepatic Antiviral Drug Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Hepatic Antiviral Drug Players to Combat Covid-19 Impact
Table 16. Global Hepatic Antiviral Drug Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global Hepatic Antiviral Drug Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global Hepatic Antiviral Drug Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global Hepatic Antiviral Drug Market Share by Regions (2015-2020)
Table 20. Global Hepatic Antiviral Drug Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global Hepatic Antiviral Drug Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. Hepatic Antiviral Drug Market Growth Strategy
Table 26. Main Points Interviewed from Key Hepatic Antiviral Drug Players
Table 27. Global Hepatic Antiviral Drug Revenue by Players (2015-2020) (Million US$)
Table 28. Global Hepatic Antiviral Drug Market Share by Players (2015-2020)
Table 29. Global Top Hepatic Antiviral Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Antiviral Drug as of 2019)
Table 30. Global Hepatic Antiviral Drug by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players Hepatic Antiviral Drug Product Solution and Service
Table 33. Date of Enter into Hepatic Antiviral Drug Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Hepatic Antiviral Drug Market Size by Type (2015-2020) (Million US$)
Table 36. Global Hepatic Antiviral Drug Market Size Share by Type (2015-2020)
Table 37. Global Hepatic Antiviral Drug Revenue Market Share by Type (2021-2026)
Table 38. Global Hepatic Antiviral Drug Market Size Share by Application (2015-2020)
Table 39. Global Hepatic Antiviral Drug Market Size by Application (2015-2020) (Million US$)
Table 40. Global Hepatic Antiviral Drug Market Size Share by Application (2021-2026)
Table 41. North America Key Players Hepatic Antiviral Drug Revenue (2019-2020) (Million US$)
Table 42. North America Key Players Hepatic Antiviral Drug Market Share (2019-2020)
Table 43. North America Hepatic Antiviral Drug Market Size by Type (2015-2020) (Million US$)
Table 44. North America Hepatic Antiviral Drug Market Share by Type (2015-2020)
Table 45. North America Hepatic Antiviral Drug Market Size by Application (2015-2020) (Million US$)
Table 46. North America Hepatic Antiviral Drug Market Share by Application (2015-2020)
Table 47. Europe Key Players Hepatic Antiviral Drug Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players Hepatic Antiviral Drug Market Share (2019-2020)
Table 49. Europe Hepatic Antiviral Drug Market Size by Type (2015-2020) (Million US$)
Table 50. Europe Hepatic Antiviral Drug Market Share by Type (2015-2020)
Table 51. Europe Hepatic Antiviral Drug Market Size by Application (2015-2020) (Million US$)
Table 52. Europe Hepatic Antiviral Drug Market Share by Application (2015-2020)
Table 53. China Key Players Hepatic Antiviral Drug Revenue (2019-2020) (Million US$)
Table 54. China Key Players Hepatic Antiviral Drug Market Share (2019-2020)
Table 55. China Hepatic Antiviral Drug Market Size by Type (2015-2020) (Million US$)
Table 56. China Hepatic Antiviral Drug Market Share by Type (2015-2020)
Table 57. China Hepatic Antiviral Drug Market Size by Application (2015-2020) (Million US$)
Table 58. China Hepatic Antiviral Drug Market Share by Application (2015-2020)
Table 59. Japan Key Players Hepatic Antiviral Drug Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players Hepatic Antiviral Drug Market Share (2019-2020)
Table 61. Japan Hepatic Antiviral Drug Market Size by Type (2015-2020) (Million US$)
Table 62. Japan Hepatic Antiviral Drug Market Share by Type (2015-2020)
Table 63. Japan Hepatic Antiviral Drug Market Size by Application (2015-2020) (Million US$)
Table 64. Japan Hepatic Antiviral Drug Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players Hepatic Antiviral Drug Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players Hepatic Antiviral Drug Market Share (2019-2020)
Table 67. Southeast Asia Hepatic Antiviral Drug Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia Hepatic Antiviral Drug Market Share by Type (2015-2020)
Table 69. Southeast Asia Hepatic Antiviral Drug Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia Hepatic Antiviral Drug Market Share by Application (2015-2020)
Table 71. India Key Players Hepatic Antiviral Drug Revenue (2019-2020) (Million US$)
Table 72. India Key Players Hepatic Antiviral Drug Market Share (2019-2020)
Table 73. India Hepatic Antiviral Drug Market Size by Type (2015-2020) (Million US$)
Table 74. India Hepatic Antiviral Drug Market Share by Type (2015-2020)
Table 75. India Hepatic Antiviral Drug Market Size by Application (2015-2020) (Million US$)
Table 76. India Hepatic Antiviral Drug Market Share by Application (2015-2020)
Table 77. Central & South America Key Players Hepatic Antiviral Drug Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players Hepatic Antiviral Drug Market Share (2019-2020)
Table 79. Central & South America Hepatic Antiviral Drug Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America Hepatic Antiviral Drug Market Share by Type (2015-2020)
Table 81. Central & South America Hepatic Antiviral Drug Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America Hepatic Antiviral Drug Market Share by Application (2015-2020)
Table 83. Teva Pharmaceutical Industries Company Details
Table 84. Teva Pharmaceutical Industries Business Overview
Table 85. Teva Pharmaceutical Industries Product
Table 86. Teva Pharmaceutical Industries Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 87. Teva Pharmaceutical Industries Recent Development
Table 88. Bristol-Myers Squibb Company Details
Table 89. Bristol-Myers Squibb Business Overview
Table 90. Bristol-Myers Squibb Product
Table 91. Bristol-Myers Squibb Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 92. Bristol-Myers Squibb Recent Development
Table 93. Zydus Cadila Company Details
Table 94. Zydus Cadila Business Overview
Table 95. Zydus Cadila Product
Table 96. Zydus Cadila Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 97. Zydus Cadila Recent Development
Table 98. Cipla Company Details
Table 99. Cipla Business Overview
Table 100. Cipla Product
Table 101. Cipla Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 102. Cipla Recent Development
Table 103. Prinston Pharmaceutical Company Details
Table 104. Prinston Pharmaceutical Business Overview
Table 105. Prinston Pharmaceutical Product
Table 106. Prinston Pharmaceutical Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 107. Prinston Pharmaceutical Recent Development
Table 108. Hetero Drug Company Details
Table 109. Hetero Drug Business Overview
Table 110. Hetero Drug Product
Table 111. Hetero Drug Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 112. Hetero Drug Recent Development
Table 113. Aurobindo Pharma Company Details
Table 114. Aurobindo Pharma Business Overview
Table 115. Aurobindo Pharma Product
Table 116. Aurobindo Pharma Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 117. Aurobindo Pharma Recent Development
Table 118. Apotex Business Overview
Table 119. Apotex Product
Table 120. Apotex Company Details
Table 121. Apotex Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 122. Apotex Recent Development
Table 123. Gilead Sciences Company Details
Table 124. Gilead Sciences Business Overview
Table 125. Gilead Sciences Product
Table 126. Gilead Sciences Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 127. Gilead Sciences Recent Development
Table 128. Mylan Company Details
Table 129. Mylan Business Overview
Table 130. Mylan Product
Table 131. Mylan Revenue in Hepatic Antiviral Drug Business (2015-2020) (Million US$)
Table 132. Mylan Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of FiguresFigure 1. Global Hepatic Antiviral Drug Market Share by Type: 2020 VS 2026
Figure 2. Entecavir Features
Figure 3. Tenofovir Features
Figure 4. lamivudine Features
Figure 5. Adefovir Features
Figure 6. Telbivudine Features
Figure 7. Others Features
Figure 8. Global Hepatic Antiviral Drug Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Homecare Case Studies
Figure 11. Clinics Case Studies
Figure 12. Others Case Studies
Figure 13. Hepatic Antiviral Drug Report Years Considered
Figure 14. Global Hepatic Antiviral Drug Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Hepatic Antiviral Drug Market Share by Regions: 2020 VS 2026
Figure 16. Global Hepatic Antiviral Drug Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Hepatic Antiviral Drug Market Share by Players in 2019
Figure 19. Global Top Hepatic Antiviral Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Antiviral Drug as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Hepatic Antiviral Drug Revenue in 2019
Figure 21. North America Hepatic Antiviral Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Hepatic Antiviral Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Hepatic Antiviral Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Hepatic Antiviral Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Hepatic Antiviral Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Hepatic Antiviral Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Hepatic Antiviral Drug Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Teva Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Teva Pharmaceutical Industries Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 30. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Bristol-Myers Squibb Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 32. Zydus Cadila Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Zydus Cadila Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 34. Cipla Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Cipla Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 36. Prinston Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Prinston Pharmaceutical Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 38. Hetero Drug Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Hetero Drug Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 40. Aurobindo Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Aurobindo Pharma Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 42. Apotex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Apotex Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 44. Gilead Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Gilead Sciences Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 46. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Mylan Revenue Growth Rate in Hepatic Antiviral Drug Business (2015-2020)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed